Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc/ US92532F1003 /
VX1/D
|
24/04/2024 17:25:19
|
Chg.
-
|
Volume |
Bid17:29:24 |
Ask17:29:24 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
373.95EUR
|
-
|
5
Turnover: 1,869.75 |
-Bid Size: - |
-Ask Size: - |
118.46 bill.EUR |
- |
- |
Business description
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Management board & Supervisory board
| CEO |
| Reshma Kewalramani, M.D. |
| Management board |
| Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D. |
| Supervisory board |
| Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay |
Company data
| Name: |
Vertex Pharmaceuticals Inc. |
| Address: |
50 Northern Avenue,Boston, Massachusetts 02210, USA |
| Phone: |
+1-617-961-7163 |
| Fax: |
- |
| E-mail: |
Investorinfo@VRTX.com
|
| Internet: |
www.vrtx.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
82.70% |
| IPO date: |
24/07/1991 |
Main Shareholders
| Others |
|
53.31% |
| Vanguard Group |
|
8.63% |
| BlackRock Inc. |
|
8.48% |
| Capital World Investors |
|
8.45% |
| FMR LLC. |
|
5.03% |
| State Street Corporation |
|
4.68% |
| ALLIANCEBERNSTEIN L P |
|
2.73% |
| PRICE T ROWE ASSOCIATES INC MD |
|
2.28% |
| GEODE CAPITAL MANAGEMENT LLC |
|
2.20% |
| Others |
|
4.21% |
